HEADER TRANSFERASE/ANTIBIOTIC 20-MAR-12 4E8J OBSLTE 05-NOV-14 4E8J 4WH5 TITLE CRYSTAL STRUCTURE OF LINCOSAMIDE ANTIBIOTIC ADENYLYLTRANSFERASE LNUA, TITLE 2 LINCOMYCIN-BOUND COMPND MOL_ID: 1; COMPND 2 MOLECULE: LINCOSAMIDE RESISTANCE PROTEIN; COMPND 3 CHAIN: A, B; COMPND 4 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: STAPHYLOCOCCUS HAEMOLYTICUS; SOURCE 3 ORGANISM_TAXID: 1283; SOURCE 4 GENE: LINA; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: P15TV LIC KEYWDS STRUCTURAL GENOMICS, ANTIBIOTIC RESISTANCE, CENTER FOR STRUCTURAL KEYWDS 2 GENOMICS OF INFECTIOUS DISEASES (CSGID), ALPHA+BETA STRUCTURE, KEYWDS 3 AMINOGLYCOSIDE-2''-ADENYLYLTRANSFERASE SUPERFAMILY, KEYWDS 4 NUCLEOTIDYLTRANSFERASE SUPERFAMILY, TRANSFERASE, LINCOSAMIDE KEYWDS 5 ADENYLYLTRANSFERASE, LINCOSAMIDE ANTIBIOTICS, LINCOMYCIN, KEYWDS 6 CLINDAMYCIN, ADENOSINE TRIPHOSPHATE, INTRACELLULAR, TRANSFERASE- KEYWDS 7 ANTIBIOTIC COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR P.J.STOGIOS,A.DONG,G.MINASOV,E.EVDOKIMOVA,O.EGOROVA,M.KUDRITSKA, AUTHOR 2 V.YIM,P.COURVALIN,A.SAVCHENKO,W.F.ANDERSON,CENTER FOR STRUCTURAL AUTHOR 3 GENOMICS OF INFECTIOUS DISEASES (CSGID) REVDAT 4 05-NOV-14 4E8J 1 OBSLTE REVDAT 3 30-APR-14 4E8J 1 COMPND JRNL REMARK TITLE REVDAT 2 18-APR-12 4E8J 1 REMARK REVDAT 1 04-APR-12 4E8J 0 JRNL AUTH P.J.STOGIOS,A.DONG,G.MINASOV,E.EVDOKIMOVA,O.EGOROVA, JRNL AUTH 2 M.KUDRITSKA,V.YIM,P.COURVALIN,A.SAVCHENKO,W.F.ANDERSON, JRNL AUTH 3 CENTER FOR STRUCTURAL GENOMICS OF INFECTIOUS DISEASES JRNL AUTH 4 (CSGID) JRNL TITL CRYSTAL STRUCTURE OF LINCOSAMIDE ANTIBIOTIC JRNL TITL 2 ADENYLYLTRANSFERASE LNUA, LINCOMYCIN-BOUND JRNL REF TO BE PUBLISHED JRNL REFN REMARK 2 REMARK 2 RESOLUTION. 1.82 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (PHENIX.REFINE: 1.7.3_928) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE- REMARK 3 : KUNSTLEVE,LI-WEI HUNG,ROBERT IMMORMINO, REMARK 3 : TOM IOERGER,AIRLIE MCCOY,ERIK MCKEE,NIGEL REMARK 3 : MORIARTY,REETAL PAI,RANDY READ,JANE REMARK 3 : RICHARDSON,DAVID RICHARDSON,TOD ROMO,JIM REMARK 3 : SACCHETTINI,NICHOLAS SAUTER,JACOB SMITH, REMARK 3 : LAURENT STORONI,TOM TERWILLIGER,PETER REMARK 3 : ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.82 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 23.35 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.430 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.6 REMARK 3 NUMBER OF REFLECTIONS : 37671 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.198 REMARK 3 R VALUE (WORKING SET) : 0.196 REMARK 3 FREE R VALUE : 0.234 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.300 REMARK 3 FREE R VALUE TEST SET COUNT : 1996 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 23.3514 - 4.3778 0.99 2616 150 0.2065 0.2091 REMARK 3 2 4.3778 - 3.4785 1.00 2584 142 0.1716 0.2154 REMARK 3 3 3.4785 - 3.0399 1.00 2552 146 0.1832 0.2216 REMARK 3 4 3.0399 - 2.7624 1.00 2562 136 0.2018 0.2550 REMARK 3 5 2.7624 - 2.5647 1.00 2540 153 0.2029 0.2413 REMARK 3 6 2.5647 - 2.4136 1.00 2586 138 0.1969 0.2465 REMARK 3 7 2.4136 - 2.2929 1.00 2553 141 0.1937 0.2228 REMARK 3 8 2.2929 - 2.1931 1.00 2540 141 0.1826 0.2510 REMARK 3 9 2.1931 - 2.1088 1.00 2546 144 0.1775 0.2102 REMARK 3 10 2.1088 - 2.0360 1.00 2541 142 0.1816 0.2132 REMARK 3 11 2.0360 - 1.9724 1.00 2545 139 0.1995 0.2658 REMARK 3 12 1.9724 - 1.9160 1.00 2540 142 0.2141 0.2948 REMARK 3 13 1.9160 - 1.8656 1.00 2543 141 0.2526 0.3036 REMARK 3 14 1.8656 - 1.8200 0.97 2427 141 0.3096 0.3587 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.47 REMARK 3 K_SOL : 0.40 REMARK 3 B_SOL : 63.38 REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.260 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 21.880 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.09080 REMARK 3 B22 (A**2) : -0.39340 REMARK 3 B33 (A**2) : 0.30260 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : -1.83300 REMARK 3 B23 (A**2) : -0.00000 REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.011 2807 REMARK 3 ANGLE : 1.378 3815 REMARK 3 CHIRALITY : 0.098 405 REMARK 3 PLANARITY : 0.006 492 REMARK 3 DIHEDRAL : 15.744 1028 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 4 REMARK 3 TLS GROUP : 1 REMARK 3 SELECTION: chain A and resi 4:94 REMARK 3 ORIGIN FOR THE GROUP (A): -25.6428 -1.3850 -22.7720 REMARK 3 T TENSOR REMARK 3 T11: 0.0177 T22: 0.0388 REMARK 3 T33: 0.0461 T12: 0.0155 REMARK 3 T13: -0.0188 T23: -0.0019 REMARK 3 L TENSOR REMARK 3 L11: 1.2045 L22: 1.1103 REMARK 3 L33: 0.8218 L12: -0.5552 REMARK 3 L13: -0.0380 L23: -0.1368 REMARK 3 S TENSOR REMARK 3 S11: 0.0627 S12: 0.1180 S13: -0.0364 REMARK 3 S21: -0.0540 S22: -0.0289 S23: 0.1428 REMARK 3 S31: 0.0146 S32: -0.1272 S33: 0.0285 REMARK 3 TLS GROUP : 2 REMARK 3 SELECTION: chain A and resi 95:161 REMARK 3 ORIGIN FOR THE GROUP (A): -15.3337 -10.6025 -16.5130 REMARK 3 T TENSOR REMARK 3 T11: 0.0561 T22: 0.1119 REMARK 3 T33: 0.1198 T12: 0.0240 REMARK 3 T13: -0.0138 T23: -0.0046 REMARK 3 L TENSOR REMARK 3 L11: 2.1737 L22: 3.8159 REMARK 3 L33: 1.6588 L12: -0.0010 REMARK 3 L13: 0.9353 L23: 0.3664 REMARK 3 S TENSOR REMARK 3 S11: 0.1293 S12: 0.0731 S13: -0.1556 REMARK 3 S21: 0.0057 S22: -0.0502 S23: -0.0341 REMARK 3 S31: 0.1440 S32: 0.0515 S33: -0.0342 REMARK 3 TLS GROUP : 3 REMARK 3 SELECTION: chain B and resi 4:94 REMARK 3 ORIGIN FOR THE GROUP (A): -7.2598 -34.8681 1.5319 REMARK 3 T TENSOR REMARK 3 T11: 0.1048 T22: 0.0841 REMARK 3 T33: 0.0934 T12: 0.0216 REMARK 3 T13: -0.0115 T23: -0.0102 REMARK 3 L TENSOR REMARK 3 L11: 1.3959 L22: 2.2184 REMARK 3 L33: 1.7841 L12: 0.9676 REMARK 3 L13: -1.1082 L23: -1.4463 REMARK 3 S TENSOR REMARK 3 S11: -0.0540 S12: -0.0910 S13: -0.0362 REMARK 3 S21: -0.0074 S22: 0.0027 S23: 0.0314 REMARK 3 S31: 0.0857 S32: -0.0128 S33: 0.0410 REMARK 3 TLS GROUP : 4 REMARK 3 SELECTION: chain B and resi 95:161 REMARK 3 ORIGIN FOR THE GROUP (A): -10.6576 -26.8521 -10.7369 REMARK 3 T TENSOR REMARK 3 T11: 0.1043 T22: 0.0651 REMARK 3 T33: 0.1056 T12: -0.0107 REMARK 3 T13: -0.0206 T23: 0.0277 REMARK 3 L TENSOR REMARK 3 L11: 1.6823 L22: 2.2220 REMARK 3 L33: 2.0128 L12: -0.5104 REMARK 3 L13: -0.0915 L23: 0.0405 REMARK 3 S TENSOR REMARK 3 S11: -0.0625 S12: 0.1296 S13: -0.2083 REMARK 3 S21: -0.2054 S22: 0.0806 S23: 0.2950 REMARK 3 S31: 0.2151 S32: -0.2077 S33: 0.0453 REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: THE QUALITY OF THE ELECTRON DENSITY FOR REMARK 3 BOTH COPIES OF THE LIGAND LN0 WAS UNAMBIGUOUS. REFINEMENT OF THE REMARK 3 LIGAND COORDINATES WITH RESTRAINTS INCLUDING SP3 HYBRIDIZATION OF REMARK 3 C8 LEAD TO RESIDUAL FO-FC PEAKS (BOTH POSITIVE AND NEGATIVE), REMARK 3 WHILE REFINEMENT OF THE LIGAND COORDINATES WITH RESTRAINTS REMARK 3 INCLUDING SP2 HYBRIDIZATION OF C8 DID NOT. IT COULD BE THAT THE REMARK 3 HYDROXYL GROUP OF LN0 WAS OXIDIZED TO A KETONE, WHICH WOULD LEAD REMARK 3 TO C8 BEING SP2 HYBRIDIZED. REMARK 4 REMARK 4 4E8J COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 23-MAR-12. REMARK 100 THE RCSB ID CODE IS RCSB071303. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 18-OCT-11 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.3 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU MICROMAX-007 HF REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.54178 REMARK 200 MONOCHROMATOR : GRAPHITE REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS HTC REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-3000 REMARK 200 DATA SCALING SOFTWARE : HKL-3000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 37695 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.820 REMARK 200 RESOLUTION RANGE LOW (A) : 24.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 200 DATA REDUNDANCY : 3.500 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.04300 REMARK 200 FOR THE DATA SET : 16.2700 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.82 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.85 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.5 REMARK 200 DATA REDUNDANCY IN SHELL : 3.30 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : 0.17400 REMARK 200 FOR SHELL : 2.036 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHENIX (PHENIX.PHASER) REMARK 200 STARTING MODEL: CRYSTAL STRUCTURE OF LINCOSAMIDE ANTIBIOTIC REMARK 200 ADENYLYLTRANSFERASE LNUA, APO REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 55.59 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.77 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 1.4 M TRI-SODIUM CITRATE DIHYDRATE, REMARK 280 0.1 M HEPES PH 7.3, 5 MM LINCOMYCIN, VAPOR DIFFUSION, SITTING REMARK 280 DROP, TEMPERATURE 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 31.72200 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 3 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1930 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 16000 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -12.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MSE A 1 REMARK 465 LYS A 2 REMARK 465 ASN A 3 REMARK 465 MSE B 1 REMARK 465 LYS B 2 REMARK 465 ASN B 3 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN A 5 -164.31 -128.61 REMARK 500 ARG B 78 148.76 -170.11 REMARK 500 PRO B 107 -17.45 -41.15 REMARK 500 GLU B 108 -57.64 -127.86 REMARK 500 SER B 120 -147.92 -139.28 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL A 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE LN0 A 202 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE LN0 B 202 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 4E8I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF LINCOSAMIDE ANTIBIOTIC REMARK 900 ADENYLYLTRANSFERASE LNUA, APO REMARK 900 RELATED ID: CSGID-IDP91779 RELATED DB: TARGETTRACK DBREF 4E8J A 1 161 UNP P06107 LINA_STAHA 1 161 DBREF 4E8J B 1 161 UNP P06107 LINA_STAHA 1 161 SEQRES 1 A 161 MSE LYS ASN ASN ASN VAL THR GLU LYS GLU LEU PHE TYR SEQRES 2 A 161 ILE LEU ASP LEU PHE GLU HIS MSE LYS VAL THR TYR TRP SEQRES 3 A 161 LEU ASP GLY GLY TRP GLY VAL ASP VAL LEU THR GLY LYS SEQRES 4 A 161 GLN GLN ARG GLU HIS ARG ASP ILE ASP ILE ASP PHE ASP SEQRES 5 A 161 ALA GLN HIS THR GLN LYS VAL ILE GLN LYS LEU GLU ASP SEQRES 6 A 161 ILE GLY TYR LYS ILE GLU VAL HIS TRP MSE PRO SER ARG SEQRES 7 A 161 MSE GLU LEU LYS HIS GLU GLU TYR GLY TYR LEU ASP ILE SEQRES 8 A 161 HIS PRO ILE ASN LEU ASN ASP ASP GLY SER ILE THR GLN SEQRES 9 A 161 ALA ASN PRO GLU GLY GLY ASN TYR VAL PHE GLN ASN ASP SEQRES 10 A 161 TRP PHE SER GLU THR ASN TYR LYS ASP ARG LYS ILE PRO SEQRES 11 A 161 CYS ILE SER LYS GLU ALA GLN LEU LEU PHE HIS SER GLY SEQRES 12 A 161 TYR ASP LEU THR GLU THR ASP HIS PHE ASP ILE LYS ASN SEQRES 13 A 161 LEU LYS SER ILE THR SEQRES 1 B 161 MSE LYS ASN ASN ASN VAL THR GLU LYS GLU LEU PHE TYR SEQRES 2 B 161 ILE LEU ASP LEU PHE GLU HIS MSE LYS VAL THR TYR TRP SEQRES 3 B 161 LEU ASP GLY GLY TRP GLY VAL ASP VAL LEU THR GLY LYS SEQRES 4 B 161 GLN GLN ARG GLU HIS ARG ASP ILE ASP ILE ASP PHE ASP SEQRES 5 B 161 ALA GLN HIS THR GLN LYS VAL ILE GLN LYS LEU GLU ASP SEQRES 6 B 161 ILE GLY TYR LYS ILE GLU VAL HIS TRP MSE PRO SER ARG SEQRES 7 B 161 MSE GLU LEU LYS HIS GLU GLU TYR GLY TYR LEU ASP ILE SEQRES 8 B 161 HIS PRO ILE ASN LEU ASN ASP ASP GLY SER ILE THR GLN SEQRES 9 B 161 ALA ASN PRO GLU GLY GLY ASN TYR VAL PHE GLN ASN ASP SEQRES 10 B 161 TRP PHE SER GLU THR ASN TYR LYS ASP ARG LYS ILE PRO SEQRES 11 B 161 CYS ILE SER LYS GLU ALA GLN LEU LEU PHE HIS SER GLY SEQRES 12 B 161 TYR ASP LEU THR GLU THR ASP HIS PHE ASP ILE LYS ASN SEQRES 13 B 161 LEU LYS SER ILE THR MODRES 4E8J MSE A 21 MET SELENOMETHIONINE MODRES 4E8J MSE A 75 MET SELENOMETHIONINE MODRES 4E8J MSE A 79 MET SELENOMETHIONINE MODRES 4E8J MSE B 21 MET SELENOMETHIONINE MODRES 4E8J MSE B 75 MET SELENOMETHIONINE MODRES 4E8J MSE B 79 MET SELENOMETHIONINE HET MSE A 21 8 HET MSE A 75 8 HET MSE A 79 13 HET MSE B 21 8 HET MSE B 75 8 HET MSE B 79 8 HET CL A 201 1 HET LN0 A 202 27 HET LN0 B 202 27 HETNAM MSE SELENOMETHIONINE HETNAM CL CHLORIDE ION HETNAM LN0 METHYL 6,8-DIDEOXY-6-{[(4R)-1-METHYL-4-PROPYL-L- HETNAM 2 LN0 PROLYL]AMINO}-1-THIO-D-GLYCERO-ALPHA-D-GALACTO- HETNAM 3 LN0 OCTOPYRANOSID-7-ULOSE HETSYN LN0 LINCOMYCIN, OXIDIZED FORM FORMUL 1 MSE 6(C5 H11 N O2 SE) FORMUL 3 CL CL 1- FORMUL 4 LN0 2(C18 H32 N2 O6 S) FORMUL 6 HOH *419(H2 O) HELIX 1 1 THR A 7 LYS A 22 1 16 HELIX 2 2 GLY A 29 GLY A 38 1 10 HELIX 3 3 HIS A 55 ILE A 66 1 12 HELIX 4 4 GLN A 115 ASP A 117 5 3 HELIX 5 5 SER A 133 HIS A 141 1 9 HELIX 6 6 SER A 142 LEU A 146 5 5 HELIX 7 7 THR A 147 SER A 159 1 13 HELIX 8 8 THR B 7 MSE B 21 1 15 HELIX 9 9 GLY B 29 THR B 37 1 9 HELIX 10 10 HIS B 55 ILE B 66 1 12 HELIX 11 11 GLN B 115 ASP B 117 5 3 HELIX 12 12 SER B 133 HIS B 141 1 9 HELIX 13 13 THR B 147 SER B 159 1 13 SHEET 1 A 5 TYR A 25 ASP A 28 0 SHEET 2 A 5 ASP A 46 ASP A 52 -1 O ASP A 50 N TRP A 26 SHEET 3 A 5 GLY A 87 LEU A 96 1 O ILE A 94 N PHE A 51 SHEET 4 A 5 ARG A 78 HIS A 83 -1 N LEU A 81 O LEU A 89 SHEET 5 A 5 LYS A 69 TRP A 74 -1 N LYS A 69 O LYS A 82 SHEET 1 B 5 TYR A 25 ASP A 28 0 SHEET 2 B 5 ASP A 46 ASP A 52 -1 O ASP A 50 N TRP A 26 SHEET 3 B 5 GLY A 87 LEU A 96 1 O ILE A 94 N PHE A 51 SHEET 4 B 5 ILE A 102 ALA A 105 -1 O THR A 103 N ASN A 95 SHEET 5 B 5 ASN A 111 PHE A 114 -1 O TYR A 112 N GLN A 104 SHEET 1 C 2 PHE A 119 TYR A 124 0 SHEET 2 C 2 ARG A 127 ILE A 132 -1 O ARG A 127 N TYR A 124 SHEET 1 D 5 TYR B 25 ASP B 28 0 SHEET 2 D 5 ASP B 46 ASP B 52 -1 O ASP B 48 N ASP B 28 SHEET 3 D 5 GLY B 87 LEU B 96 1 O ILE B 94 N PHE B 51 SHEET 4 D 5 ARG B 78 HIS B 83 -1 N LEU B 81 O LEU B 89 SHEET 5 D 5 LYS B 69 TRP B 74 -1 N GLU B 71 O GLU B 80 SHEET 1 E 5 TYR B 25 ASP B 28 0 SHEET 2 E 5 ASP B 46 ASP B 52 -1 O ASP B 48 N ASP B 28 SHEET 3 E 5 GLY B 87 LEU B 96 1 O ILE B 94 N PHE B 51 SHEET 4 E 5 ILE B 102 ALA B 105 -1 O THR B 103 N ASN B 95 SHEET 5 E 5 ASN B 111 VAL B 113 -1 O TYR B 112 N GLN B 104 SHEET 1 F 2 PHE B 119 TYR B 124 0 SHEET 2 F 2 ARG B 127 ILE B 132 -1 O ARG B 127 N TYR B 124 LINK C HIS A 20 N MSE A 21 1555 1555 1.33 LINK C MSE A 21 N LYS A 22 1555 1555 1.33 LINK C TRP A 74 N MSE A 75 1555 1555 1.32 LINK C MSE A 75 N PRO A 76 1555 1555 1.35 LINK C ARG A 78 N MSE A 79 1555 1555 1.33 LINK C MSE A 79 N GLU A 80 1555 1555 1.33 LINK C HIS B 20 N MSE B 21 1555 1555 1.32 LINK C MSE B 21 N LYS B 22 1555 1555 1.33 LINK C TRP B 74 N MSE B 75 1555 1555 1.33 LINK C MSE B 75 N PRO B 76 1555 1555 1.34 LINK C ARG B 78 N MSE B 79 1555 1555 1.33 LINK C MSE B 79 N GLU B 80 1555 1555 1.33 CISPEP 1 MSE A 75 PRO A 76 0 8.76 CISPEP 2 MSE B 75 PRO B 76 0 9.53 SITE 1 AC1 5 GLN A 115 ASN A 116 HOH A 320 HOH A 379 SITE 2 AC1 5 LYS B 155 SITE 1 AC2 11 ASP A 28 GLY A 29 GLY A 30 ASP A 50 SITE 2 AC2 11 HIS A 92 PHE A 119 GLN A 137 PHE A 140 SITE 3 AC2 11 HOH A 331 HOH A 445 TYR B 144 SITE 1 AC3 16 TYR A 144 ASP B 28 ASP B 48 ASP B 50 SITE 2 AC3 16 ARG B 78 ASP B 90 HIS B 92 GLN B 104 SITE 3 AC3 16 PHE B 119 PHE B 140 HOH B 355 HOH B 383 SITE 4 AC3 16 HOH B 500 HOH B 513 HOH B 516 HOH B 526 CRYST1 56.447 63.444 60.808 90.00 101.60 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017716 0.000000 0.003635 0.00000 SCALE2 0.000000 0.015762 0.000000 0.00000 SCALE3 0.000000 0.000000 0.016788 0.00000